Skip to content

Coronary Microvascular Dysfunction Assessments in Myocardial Infarction With Non-Obstructive Coronary Arteries

Clinical Relevance of Coronary Microvascular Dysfunction Assessments in Myocardial Infarction With Non-Obstructive Coronary Arteries

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05272618
Acronym
CMD-MINOCA
Enrollment
150
Registered
2022-03-09
Start date
2022-02-14
Completion date
2030-12-31
Last updated
2026-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Microvascular Dysfunction, Myocardial Infarction, Vasospasm, Coronary

Keywords

MINOCA, Coronary physiology, Cardiac PET, CFR, IMR, OCT

Brief summary

To compare clinical outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA) according to the coronary microvascular dysfunction (CMD), evaluated by optical coherence tomography (OCT), invasive and non-invasive coronary physiologic assessment.

Detailed description

Background Approximately 5\ 10% of patients with acute myocardial infarction (AMI) have been reported as myocardial infarction with non-obstructive coronary arteries (MINOCA) in the contemporary clinical setting. Although those with MINOCA have a better prognosis than with obstructive coronary artery disease, several observational studies continuously reported that patients with MINOCA showed comparable outcomes. One plausible explanation of this discrepancy is the heterogeneous and variable definition of MINOCA. Possible causes of MINOCA include plaque erosion and/or rupture, vasospasm, and CMD. Therefore, it is natural that heterogeneous pathophysiology of MINOCA causes diagnostic challenges and proper management. Recently, there have been efforts for establishing the diagnosis of MINOCA and standardizing the systematic management according to the cause of MINOCA. According to the AHA scientific statement, patients who suspected MINOCA have been recommended to perform multimodality approach, including intravascular imaging (i.e., OCT). Although non-invasive methods, such as N-13 ammonia positron emission tomography (PET), can be used for evaluating the CMD, invasive coronary physiologic assessment using pressure-temperature wire has been recommended. CMD has been known as a major cause of MINOCA, and it may be required specific treatment. Nevertheless, there has no data on the outcomes of MINOCA with or without CMD. Therefore, the aim of CMD-MINOCA sought to assess the MINOCA patients regarding the latest clinical pathway for diagnosis of CMD and evaluate their clinical outcomes at 2 years.

Interventions

DIAGNOSTIC_TESTIntravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)

Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)

Sponsors

Chonnam National University Hospital
Lead SponsorOTHER
Korean Cardiac Research Foundation
CollaboratorUNKNOWN
Abbott
CollaboratorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subject with age ≥19 years and acute myocardial infarction * Rise and/or fall of cardiac troponin with one level \>99 percentile plus ischemic signs/symptoms * Subject with non-obstructive coronary arteries * \<50% diameter stenosis or * fractional flow reserve (FFR) \>0.80 ③ Subject without previous history of coronary artery disease * Subject who performed invasive coronary angiography within 24 hours after presentation ⑤ Subject who eligible for invasive and non-invasive coronary physiologic assessment

Exclusion criteria

* Subject with obstructive coronary arteries * Subject with alternate diagnosis including sepsis, pulmonary embolism, myocarditis, Takotsubo syndrome, spontaneous coronary dissection, and other cardiomyopathies. * Subject with cardiogenic shock or cardiac arrest ④ Subject who has non-cardiac co-morbid conditions with life expectancy \<1 year ⑤ Subject or lactating women ⑥ Subject unable to provide consent

Design outcomes

Primary

MeasureTime frameDescription
MACCE2-Year after enrollmenta composite of cardiac death, any MI, any revascularization, stroke, readmission due to heart failure

Secondary

MeasureTime frameDescription
cardiac death2-Year after enrollmentdeath from cardiac-cause
all-cause death2-Year after enrollmentdeath from any-cause
Rate of myocardial infarction2-Year after enrollmentany type of myocardial infarction
Rate of repeat revascularization2-Year after enrollmentischemia-driven or all
Rate of stroke2-Year after enrollmentischemic or hemorrhagic stroke by brain imaging
re-admission due to heart failure2-Year after enrollmentre-admission due to heart failure
all-cause death, any MI, or any revascularization2-Year after enrollmenta composite of all-cause death, any myocardial infarction, or any revascularization
Changes of left ventricular ejection fraction2-Year after enrollmentleft ventricular ejection fraction by echocardiography
Changes of Coronary flow reserve6-Month after enrollmentCoronary flow reserve by PET

Countries

South Korea

Contacts

CONTACTYoung Joon Hong, MD, PhD
hyj200@hanmail.net82-10-2055-7919
CONTACTSeung Hun Lee, MD, PhD
lsh8602@naver.com82-10-6413-7449
PRINCIPAL_INVESTIGATORYoung Joon Hong, MD, PhD

Chonnam National University Medical School; Chonnam National University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 13, 2026